CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase I/II Trial to Evaluate the Safety and Tolerability of Clazakizumab (Anti-IL-6 Monoclonal) As an Agent to Eliminate Donor Specific HLA Antibodies and Improve Outcomes of Patients With Chronic & Active Antibody-Mediated Rejection Post-Kidney Transplantation

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03380377
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:27:50.070289+00:00
Published At: 2025-05-06T00:00:00+00:00
Record Updated At: 2025-05-06
Results Posted At: 2025-05-06
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Antibody-mediated Rejection", "Kidney Transplant; Complications", "Transplant Glomerulopathy", "Transplant Glomerulopathy - Late Form", "Transplant Glomerulopathy - Early Form", "Kidney Transplant Rejection"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-05-06"
protocolSection.identificationModule.nctId: "NCT03380377"
protocolSection.identificationModule.officialTitle: "A Phase I/II Trial to Evaluate the Safety and Tolerability of Clazakizumab (Anti-IL-6 Monoclonal) As an Agent to Eliminate Donor Specific HLA Antibodies and Improve Outcomes of Patients With Chronic \u0026 Active Antibody-Mediated Rejection Post-Kidney Transplantation"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2025-05-06"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.